Briacell Therap (NASDAQ:BCTX) Shares Up 1.8% – Here’s What Happened

Briacell Therap (NASDAQ:BCTX)’s share price shot up 1.8% during mid-day trading on Tuesday . The company traded as high as $3.58 and last traded at $3.45. Approximately 61,830 shares were traded during mid-day trading, a decline of 41% from the average session volume of 105,626 shares. The stock had previously closed at $3.39.

Wall Street Analyst Weigh In

BCTX has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Briacell Therap presently has a consensus rating of “Sell”.

Briacell Therap Stock Up 0.9%

The firm has a market cap of $29.93 million, a PE ratio of -0.43 and a beta of 1.14. The firm has a 50-day moving average price of $3.34 and a two-hundred day moving average price of $3.81.

Briacell Therap (NASDAQ:BCTX) last issued its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) EPS for the quarter.

Institutional Investors Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Flagship Harbor Advisors LLC purchased a new stake in Briacell Therap (NASDAQ:BCTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned about 0.21% of Briacell Therap as of its most recent filing with the Securities and Exchange Commission (SEC). 15.42% of the stock is currently owned by institutional investors and hedge funds.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.